This section considers consumer reaction to the debate between genetically modified food and conventionally grown crops.

A recent decision of the Australian Patent Office has clearly stated that Swiss-style claims cover the manufacture of a medicament wherein the medicament is intended for a specific medical treatment, but do not extend to the method of medical treatment itself.

NSW police can issue drug penalty notices, or on-the-spot fines, for possession of small quantities of drugs.

Fear of getting into trouble with the law is a major barrier to seeking medical help when illicit drug use is involved.

The prosecution argued that the offender had committed the offence of supplying prohibited drugs on an ongoing basis.

This article includes the growth of the Australian cannabis market and managing the associated money laundering risks.

Manufacturers and suppliers of these sports supplements should ensure that they are registered as medicines on the ARTG.

On July 7, 2013, the Canadian Food Inspection Agency (CFIA) released a discussion document.

The impact of international tariffs means farmers and growers across the country are under immense pressure.

A weekly summary of the critical judgments, legislation, press releases and news items relevant to the health industry.

This newsletter includes links and summaries to recent media releases, recalls and alerts relating to healthcare law.

The Pharmacy Board of Australia has released guidelines for the supply of medicinal cannabis.

A prisoner made an application to Queensland Corrective Services seeking to have some of her eggs extracted and frozen so that she may undergo ‘assisted reproductive technology’ upon her release from imprisonment.

Explanation of repurposing medicines & the 3 broad approaches outlined by TGA to encourage it.

Focus on earlier publication of major innovator prescription medicine applications.

A PTE is a useful mechanism for a patentee to extend the term of a pharmaceutical patent from the standard 20-year term.

Recent ACCC enforcement activities have focused on false credence claims in relation to food products.

From 2016, the new Standard 1.3.7 will drastically change the current food labelling and advertising regulatory system.

Infringement of a Swiss-style claim does require the pharmaceutical patentee to establish the manufacturer's intention.

This sparked interest in the potential for patentees to prevent non-patent infringing generic pharmaceutical products.